The cholesterol drug space is set to get a little more crowded, and “Fast Money” traders believe one company should benefit most.
Amgen could get approval for its new cholesterol treatment as early as next week. The medicine would compete with one already offered by Regeneron Pharmaceuticals.
Hey, check out all the research scientist jobs. Post your resume today!
